SNP Panel for Type 2 Diabetes Risk Prediction and Treatment Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diabetes management strategies fail to effectively predict type 2 diabetes (T2D) susceptibility and treatment response, particularly in Mexican and Latin American populations, and lack sufficient tools to encourage adherence to self-management programs, resulting in low adherence rates and inadequate blood sugar control in most diabetics.

Innovation Solution

A method and system for assessing T2D susceptibility and predicting treatment response by determining specific single nucleotide polymorphisms (SNPs) associated with T2D risk, including SNPs like SLC16A11-rs75493593 and TCF7L2-rs7903146, and using these genetic markers to tailor interventions such as personalized medication and behavioral games to improve adherence and management.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current diabetes management strategies are used, then diabetes care can be provided to patients, but adherence to self-management programs remains low and blood sugar control is inadequate

Engineering Contradiction:

Improveadherence to self-management programsVSAvoidease of implementing management programs

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent segments diabetes management into genetically tailored intervention pathways based on SNP profiles. Patients are divided into subgroups according to their genetic risk factors and treatment responses, allowing customized management strategies for each segment rather than a one-size-fits-all approach, thereby improving adherence through personalization.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary genetic testing and risk assessment before implementing diabetes management programs. By determining SNP profiles and predicting treatment responses in advance, the system prepares personalized intervention plans beforehand, enabling patients to follow tailored programs from the outset, which improves adherence and outcomes.

Inventive Principle:

Principle #10Preliminary action

2Quantity of substance

If genome-wide association studies are used to identify genetic variants, then more genetic loci can be discovered, but the variants explain only a small fraction of heritability

Engineering Contradiction:

Improvenumber of genetic loci identifiedVSAvoidexplanation of heritability

Core Design Contradiction:

Quantity of substanceVSMeasurement precision

Solution Approach 1:

The patent focuses on specific local genetic regions and particular SNP markers that have strong associations with diabetes risk and treatment response. Rather than treating all genetic variants equally, the system identifies and prioritizes specific high-impact loci and SNPs, providing more precise predictive power for clinical applications.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the parameter of genetic analysis from broad genome-wide scanning to targeted SNP profiling with weighted risk scoring. By transforming the approach to focus on specific genetic parameters and their combined effects, the system achieves better heritability explanation through integrated risk assessment rather than isolated variant identification.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If frequent contact is provided to support preventive care, then patient adherence can be improved, but expensive medical professional time is required

Engineering Contradiction:

Improveadherence to preventive careVSAvoidmedical professional time

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent enables patients to self-manage their diabetes care by providing them with personalized genetic risk profiles and tailored management recommendations. Patients can independently follow their customized programs without requiring frequent professional intervention, reducing the need for expensive medical time while maintaining high adherence through personalization and patient empowerment.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent implements feedback mechanisms where patients receive ongoing monitoring results and personalized recommendations based on their genetic profiles. This automated feedback system keeps patients engaged and adherent to their programs without requiring frequent direct contact with medical professionals, thus improving reliability while conserving professional time.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS11578368B2Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes

Publication Date: 2023.02.14 PATIA BIOPHARMA S A DE

AI summary

The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.